— AstraZeneca Plc (NYSE: AZN) reported its third-quarter 2019 earnings of $0.23 per share and core earnings of $0.99 per share. This is compared to $0.45 per share expected.
— Total revenue increased by 20% to $6.41 billion versus $6.18 billion expected. This is driven by a 16% jump in product sales.
— Oncology sales jumped by 46% and respiratory sales grew by 15%. Biopharmaceuticals sales increased by 12% and new CVRM sales rose by 8% while sales in other medicines fell by 9%.
— Looking ahead into the full year 2019, the company reiterates its core earnings guidance in the range of $3.50 to $3.70 per share.
— The core operating profit for fiscal 2019 is predicted to increase ahead of product sales.
— For the full year, capital expenditure is anticipated to be broadly stable and restructuring expenses are targeted to reduce versus the prior-year.
Most Popular
Walgreens Boots Alliance set to report Q2 earnings. Here’s what to expect
Walgreens Boots Alliance, Inc. (NASDAQ: WBA), a market leader in health and wellness services, is preparing to report second-quarter results, with market watchers forecasting a mixed outcome. As part of
Chewy (CHWY) is set for meaningful growth in the coming year, here’s why
Shares of Chewy, Inc. (NYSE: CHWY) stayed red on Thursday. The stock has dropped 2% over the past three months. The pet products company ended fiscal year 2024 on a
GME Earnings: GameStop Q4 2024 profit rises; sales down 28%
Video game company GameStop Corp. (NYSE: GME) has reported an increase in fourth-quarter 2024 earnings, despite a double-digit fall in revenues. Net sales decreased to $1.28 billion in the fourth
